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「Serum anti-Gal-3 autoantibody is a predictive marker of the efficacy of 
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目的 
肺腺癌の化学療法は ALKや EGFRなどの遺伝子変異に対する分子標的薬治療が広く行われ
ているが、これらの遺伝子変異のある肺腺癌患者は全体の約 35％である。これらの分子標
的薬は遺伝子変異のない肺腺癌患者には奏効性がないため、多くの患者はプラチナ製剤を
基本とした多剤併用療法が主に用いられている。プラチナ製剤は遺伝子変異の有無に関わ
らず高い治療効果があるため、一次、二次治療薬として用いられることが多い。しかし、
副作用が強く、奏効率も 20%程度であり、事前に治療効果が期待できないことが予測でき
れば、非プラチナ製剤を用いた治療に変更することも可能となる。 
本研究では、プラチナ製剤感受性予測マーカーの獲得を目指し、プラチナ製剤を用いた
治療を受け、その治療効果判定が既知である肺腺癌患者の治療前血清を一次抗体とした二
次元免疫ブロット法を行い、自己抗体利用したプラチナ製剤治療感受性予測マーカー探索
を網羅的に行った。 
 
方法 
材料：プラチナ製剤を基本とした多剤併用療法を行い、RECISTによる治療の効果判定が
既知である肺腺癌患者の治療前に採血した血清(治療前血清)と、同じく治療前に採取した
腫瘍の生検組織(治療前腫瘍組織)を用いた。 
二次元免疫ブロット法：シスプラチン耐性にした肺腺癌細胞株(シスプラチン耐性株)か
らタンパク質を抽出し、二次元電気泳動法にて展開した。PVDF膜に転写後、化学療法で奏
効群または進行群と判断されたそれぞれ 3 例の治療前混合血清を一次抗体に用いた免疫ブ
ロット法を行い、それぞれで自己抗体が認識する抗原タンパク質を検出した。その後、CBB
染色したゲルから自己抗体が認識した抗原スポットを切り出し、トリプシンを用いたゲル
内消化後、質量分析装置にて抗原タンパク質を同定した。 
Dot Blot解析：シスプラチン耐性株から抽出したタンパク質を二次元電気泳動法にて展
開後、目的とする Galectin-3 (Gal-3)のスポットをゲルから切り出し、Electro Elution
法にてタンパク質を抽出した。抽出したタンパク質を抗原とした Dot Blot 法により、22
症例の治療前血清中の自己抗体量を測定した。その後、シグナル解析ソフトウエアを用い
て進行群を判別群、奏効/安定群を対照群とした ROC解析を行った。 
免疫染色法：10％ホルマリン固定パラフィン包埋された 40例の治療前腫瘍生検組織を対
象に、一次抗体に抗 Gal-3抗体を用いて免疫染色を行った。腫瘍細胞の細胞質に明らかな
発現が認められたものを陽性、認められなかったものを陰性と評価した。 
 
結果 
治療前血清を一次抗体とした二次元免疫ブロット法(図 1)により自己抗体が認識する抗
原タンパク質は進行群で 51 種、奏効群で 12 種が同定された。今回、進行群のみで検出さ
れ、薬剤感受性との関連性が多く報告されている Gal-3に着目し、さらに検討を進めた。 
22 例の肺腺癌患者の治療前血清中の抗 Gal-3 自己抗体量を Dot Blot 解析により測定し
た結果、奏効/安定群に比して進行群で有意に抗 Gal-3 自己抗体量が増加していた(p = 
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0.0084, 図 2)。Receiver operating characteristic curve (ROC)解析では進行群を判別
群、奏効/安定群を対照群とした場合、The area under the curve (AUC)が 0.84 であり、
最適 Cut off値を 1,086 と設定した時、感度が 67％、特異度が 92％で両者を鑑別可能であ
った。 
また、肺腺癌患者の治療前腫瘍組織を用いた免疫染色の結果、Gal-3 の発現は進行群
では 15例中 10例(66.7%)、安定群では 14例中 7例(50.0%)、奏効群では 11例 2例(18.2%)
と徐々に陽性率が低下していた(図 3)。また、Gal-3タンパク質の陽性率は奏効/安定群
に比して進行群で高い傾向を示した(p = 0.0601)。 
 
考察 
Gal-3タンパク質の発現は腫瘍細胞においては、プラチナ製剤による治療で奏効/安定群
に比して非奏効群(進行群)で高い陽性率を示し、さらに進行群で血中自己抗体量が高いこ
とと、過去の報告から肺腺癌組織においてもプラチナ製剤耐性に関与していることが示唆
される。さらに、肺腺癌患者の抗 Gal-3 自己抗体量を測定することで、プラチナ製剤の治
療感受性予測が治療前の血清で容易に行える可能性を今回初めて明らかにした。 
以上の結果から、肺腺癌患者の治療前血清中の抗 Gal-3 自己抗体検査はプラチナ製剤に
よる治療後に進行する患者を事前に鑑別できる可能性が示唆され、このような患者は非プ
ラチナ製剤を用いた治療に変更するなどの治療方針の変更に役立つ可能性がある。 
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1. Introduction 
Lung cancer is one of the most common neoplasms worldwide. It is the leading cause of 
cancer-related death in Japan, and the 5-year overall survival rate is still below 16%. Non-small 
cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancers, and 
adenocarcinoma (AC) comprises about 50% of NSCLC (Jemal et al., 2007). Although 
platinum-based chemotherapy regimens improve the survival of patients with advanced NSCLC, 
resistance to chemotherapeutic agents is a major problem (Watanabe et al., 2003, Perng et al., 
2008). In clinical practice, the chemotherapy response is variable among individuals. About 
one-third of NSCLC patients achieve complete remission (CR) or a partial response (PR) 
following the standard first-line chemotherapy, while another one-third show stable disease (SD) 
and progressive disease (PD), respectively (Chang, 2011). Thus, the identification of predictive 
markers of the response to chemotherapy is an urgent issue. 
Autoantibodies are generally produced in sera of patients with various autoimmune diseases. 
They are also frequently observed in sera of patients with various neoplasms, even in the early 
stages. Therefore, the possibilities of using them as potential tumor markers have been 
suggested (Naour et al., 2002; Fernández-Madrid et al., 2004; Xia et al., 2005). Hanash (Hanash, 
2003) reported that analyzing the immune response to identify novel cancer biomarkers is an 
attractive strategy, because the immune system induces biological amplification that is 
equivalent to a polymerase chain reaction (PCR) by generating a detectable signal with antigenic 
tumor proteins as templates, beginning at a very early stage during tumor development before 
the tumor identifiable. Some tumor-associated autoantibodies have also been reported for lung 
cancer (Vural et al., 2005; Yagihashi et al., 2005). Cis-diamino-dichloroplatinum (II) (cisplatin) is 
a common agent used for chemotherapy against various cancers, including lung cancer. Cisplatin 
is a cytotoxic compound, which inhibits transcription and DNA replication, and induces 
apoptosis (Gonzalez et al., 2001). For lung cancer patients, cisplatin was found to be more 
effective than radiotherapy, and the combination of cisplatin and vinorelbine improved survival 
(Pepe et al., 2007). Multiple mechanisms have been suggested to explain platinum resistance, 
such as decreased tumor blood flow, altered extracellular conditions, reduced platinum uptake, 
increased efflux, intracellular detoxification by glutathione or decreased binding, DNA repair, 
decreased mismatch repair, defective apoptosis, the activation of anti-apoptotic factors or other 
signaling pathways, or the presence of quiescent non-cycling cells (Stewart, 2007). The 
mechanisms underlying cisplatin resistance have not been fully elucidated, and 
response-predictive markers of cisplatin have not been identified, which are clinical issues. 
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In this study, we searched for novel predictive markers of the therapeutic effect of cisplatin by 
two-dimensional immunoblotting (2DE-IB) with pretreated sera from patients who showed a 
partial response (PR) or progressive disease (PD) after platinum-based chemotherapy, and found 
that anti-Galectin-3 (Gal-3) autoantibody was correlated with the efficacy of the response to 
platinumbased chemotherapy.
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2.  Materials and Methods 
2-1. Cell lines 
The LC2/ad cell line derived from lung AC was purchased from RIKEN BioResource Center 
(Ibaraki, Japan). LC2/ad cells were grown in RPMI-1640 medium (SIGMA, Steinheim, Germany) 
supplemented with 10% heat-inactivated fetal bovine serum (Biowest, Miami, FL, USA), 100 
units/mL penicillin, and 100 µg/mL streptomycin (Life Technologies Corp., Carlsbad, CA, USA). 
Cells were kept at 37℃ in a humidified atmosphere of 5% CO2 and 95% air. Harvested cells were 
washed twice with phosphate-buffered saline without bivalent ions (PBS-) and stored at -80℃. A 
cisplatin-resistant sub-line (LC2/ad-cis) was previously established and stably grown with a 
concentration of 3,200 ng/mL cisplatin for over 12 months in our laboratory (Kageyama et al., 
2011). After harvesting and washing twice with PBS-, LC2/ad-cis cells were stored at -80℃. 
 
2-2. Serum and tissue samples 
The pre-treated sera from 22 patients with lung AC, who received platinum-based 
chemotherapy at Kitasato University Hospital, were collected and stored at -80˚C until use. The 
number of underwent platinum-based chemotherapy and responses are shown in Table 1. Eight 
patients received cisplatin-based chemotherapy, including gemcitabine for 7 patients and 
docetaxel for the remaining one. Fourteen patients were treated with carboplatin-based 
chemotherapy, including 3 with gemcitabine, 2 with docetaxel, and 9 with paclitaxel. The 
responses to the chemotherapies were assessed by RECIST (version 1. 1), and as shown in Table 
1, 7 patients showed PR, 6 showed SD, and 9 showed PD. Pre-treatment biopsy samples from 40 
lung AC patients who received platinum-based chemotherapy, at Kitasato University Hospital 
were used in this study. Among the 40 patients, 30 were treated with cisplatin-based regimens 
including 22 with gemcitabine, 7 with irinotecan, and 1 with etoposide. The remaining 10 
patients were treated with carboplatin-based chemotherapy: 8 with paclitaxel and 2 with 
etoposide. The responses to the chemotherapies were assessed as PR in 11, SD in 14, and PD in 
15 patients. All samples were collected in accordance with the ethical guidelines and written 
consent mandated, and this study was approved by the Ethics Committee of Kitasato University 
School of Medicine (B07-06). All patients were approached based on approved ethical guidelines, 
and all agreed to participate in this study and provided written consent. Patients could refuse 
entry and discontinue participation at any time. 
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2-3. Two-dimensional gel electrophoresis-immunoblotting 
Two-dimensional gel electrophoresis with agarose (agarose 2-DE) method was performed with 
minor modifications to make it suitable for mini-gel (Nagashio et al., 2008). In brief, LC2/ad-cis 
cells were solubilized in lysis buffer [7 M urea, 2 M thiourea, 2% 3-[(3-cholamidopropyl) 
dimethylammonio] propanesulfonic acid, 0.1 M dithiothreitol, 2.5% pH 3-10 Pharmalyte (GE 
Healthcare Bio-Sciences, Piscataway, NJ, USA), and 0.1 tablet/mL of complete mini EDTA-free 
protease inhibitors (Roche Diagnostics, Mannheim, Germany)] using an ultrasonic homogenizer 
(VP-050; TAITEC, Saitama, Japan), and centrifuged at 20,000 x g for 30 min at 4℃. The protein 
was performed using 2-D Clean-Up Kit (GE Healthcare). The first-dimensional agarose 
isoelectric focusing (IEF) gel (80 mm long, 2.5-mm inner diameter) was made using a single pH 
3-10 pharmalyte. The extracted proteins were applied to the cathodic end of the agarose IEF gel, 
and loaded at 4℃ in stepwise voltages (1 hr at 100 V, 1 hr at 300 V, 1 hr at 500 V, 2 hrs at 700 V, 
and 3 hrs at 900 V). Then, the gels were immersed in trichloroacetic acid (TCA)-fixative solution 
(10% trichloroacetic acid, 5% sulfosalicylic acid) for 3 min at room temperature (RT) with 
shaking. After rinsing in distilled water (DW) three times for 15 min each, gels were treated in 
sodium dodecylsulfate (SDS) solutions (0.05 M Tris-HCl pH 6.8, 2% sodium dodecyl sulfate, 10% 
glycerol, 5% mercaptoethanol, and 0.02% bromophenol blue) for 15 min at RT with mild shaking. 
Then, each agarose gel was placed on the top of the second dimensional SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE) gel with 12% polyacrylamide gel (7-9 cm), and loaded with a 
constant current at 20 mA. Two pieces of gel were prepared: one was for protein transfer to a 
polyvinylidene difluoride membrane (Millipore, Bedford, MA, USA) for immunoblotting, and the 
other was stained with coomassie brilliant blue R-350 (CBB) solution (PhastGel Blue R; GE 
Healthcare). After blocking with 0.5% casein/0.01 M Tris-HCl, pH 7.5, 150 mM NaCl (TBS) for 60 
min at RT, the membranes were reacted with 100-times-diluted pre-treated sera from three lung 
AC patients who were assessed as showing PR or PD after platinum-based chemotherapy with 
0.5% casein/TBS-T (TBS containing 0.1% Tween20) overnight at RT. Then, the membranes were 
reacted with 1,000-times-diluted horseradish peroxidase (HRP)- conjugated rabbit anti-human 
IgG polyclonal antibody (Dako, Glostrup, Denmark) with 0.5% casein/TBS-T for 30 min at RT. 
Finally, immunoreactive spots on the membranes were visualized with the Stable DAB solution 
(Lifetechnologies Corp.). 
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2-4. Identification of proteins recognized by autoantibodies 
The protein spots matched with the immunoreactive spots were manually excised from 
CBB-stained 2-DE gels and destained with 50% acetonitrile (ACN)/50 mM NH4HCO3. The 
pieces of gel were dehydrated with 100% ACN and dried under vacuum conditions. Continuously, 
they were rehydrated in 10 µL of digestion solution containing 10 ng/μL trypsin (Trypsin Gold, 
Mass Spectrometry Grade, Promega, Madison, WI, USA) for 45 min at 4℃, and then incubated 
for 24 hrs at 37℃ with a minimum volume of 25 mM NH4HCO3. After incubation, digested 
tryptic peptide solutions were collected, and the gel was washed once with 50% ACN/5% 
trifluoroacetic acid and collected in the same tube. Solutions containing digested tryptic peptide 
were then subjected to peptide mass fingerprint (PMF) and MS/ MS analyses for protein 
identification with autoflex Ⅲ matrix assisted laser desorption ionization-time of flight/ time of 
flight mass spectrometry (MALDI-TOF/TOF MS, Bruker Daltonics GmbH, Bremen, Germany). 
The PMF and MS/MS spectra were submitted to MASCOT (http:// www.matrixscience.com/) for a 
database search, and the identification of corresponding proteins was conducted with the 
following database: IPI human database version 3.85 (89,952 sequences; 36,291,020 residues, 
http://www. ebi.ac.uk/IPI/IPIhuman.). 
 
2-5. One-dimensional gel electrophoresis immunoblotting 
Proteins were extracted from lung cancer cell lines with detergent lysis buffer (Laemmli, 1970) 
using an ultra-sonic homogenizer (VP-050; TAITEC). Each 10 μg of extracted proteins was boiled 
and separated by SDS-PAGE using 10% gel with a constant current at 20 mA. After being 
transferred onto a PVDF membrane and blocked with 0.5% casein/TBS-T for 60 min at RT, the 
membranes were reacted with 500-times-diluted antiGal-3 antibody (Leica Biosystems, Milton 
Keynes, UK) with 0.5% casein/TBS-T for 2 hrs at RT. The membranes were continuously reacted 
with 1,000-times-diluted HRPconjugated rabbit anti-mouse IgG polyclonal antibody (Dako) with 
0.5% casein/TBS for 30 min at RT. Finally, immunoreactive bands on the membranes were 
detected with Chemiluminescent HRP Substrate (Millipore Corp.), and captured with ATTO Cool 
Saver System (ATTO, Tokyo, Japan). 
 
2-6. Immunohistochemistry 
Ten percent formalin-fixed and paraffin-embedded lung cancer cell lines and lung AC biopsy 
specimens were used for IHC. Three-micrometer-thick sections were deparaffinized in xylene 
and rehydrated in a descending ethanol series, and then treated with 3% hydrogen peroxide for 
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10 min. After blocking with 2% normal swine serum (NSS)/TBS for 10 min at RT, the sections 
were reacted with 200-times-diluted anti-Gal-3 antibody with 2% NSS/TBS for 16-18 hrs at RT. 
Then, the sections were reacted with ChemMate ENVISION reagent (Dako) for 30 min at RT. 
Finally, the sections were visualized using Stable DAB solution (Invitrogen) and counterstained 
with Mayer’s hematoxylin. 
 
2-7. Evaluation of immunohistochemistry 
Cytoplasmic immunostaining of tumor cells was considered to be a positive result for anti-Gal-3 
autoantibody. The staining intensity was categorized into four groups: 0=negative; 1=weakly 
positive; 2=moderately positive, 3=strongly positive. The tumor cells with staining scores of 2 
and 3 were judged as positive. The X2 -test was used for the statistical evaluation of staining 
data. p < 0.05 was considered significant. 
 
2-8. Preparation of Gal-3 protein for dot-blot analysis 
ⅰ) Electro-elution method 
Protein extraction from the CBB-stained 2-DE gels were performed using Mini GeBA (Gene 
Bio-Application Ltd., Yavne, Israel) according to the manufacturer ’s instructions. In brief, a 
Gal-3 protein spot was excised from 2-DE gel and transferred to a Mini GeBAflex-tube. After 
being filled with proteinrunning buffer (0.192 M glycine, 0.025 M Tris-HCl pH 7.5, and 0.1% 
SDS) and placed in the supporting tray, the tube was loaded at 100 V until the protein exited the 
gel slice using a mini-gel electrophoresis chamber (Mupid, ADVANCE CO., Ltd., Saitama, 
Japan). Next, reversing the polarity of the electric current for 120 sec, the protein-containing 
solution was transferred to a clean tube. Then, an equal volume of 20% TCA was added to the 
tube and it was incubated for 1 hr at 4℃, centrifuged at 18,000 x g for 30 min at 4℃, and the 
supernatant was discarded. After adding cold acetone, the sample was incubated at -20℃ for 1 hr, 
and then centrifuged at 18,000 x g for 30 min at 4℃. Finally, the supernatant was discarded, the 
pellet was air-dried, and Gal-3 protein was solubilized with detergent lysis buffer using an 
ultra-sonic homogenizer. 
ⅱ)Recombinant Gal-3 protein 
Recombinant Gal-3 protein was prepared using a wheat germ cell-free system (Goshima et al., 
2008). Protein information and the sequence ID of recombinant Gal-3 protein are 
FLJ95838AAAF and G-BRTHA2025858_F.1, respectively 
(http://hgpd.lifesciencedb.jp/cgi/index.cgi). 
 -7- 
 
2-9. Dot blot analysis 
IgG levels of anti-Gal-3 autoantibody in sera were detected employing the automatic dot blot 
system, with a 256-solid pin configuration (Kakengeneqs Co., Ltd., Chiba, Japan). Gal-3 protein 
extracted by the electroelution method and recombinant protein were spotted onto the PVDF 
membranes. After being washed in TBS, the membranes were blocked with 2% Tween 20 in TBS 
for 1 hr at RT. Then, the membranes were reacted with 1,000-times-diluted pre-treated sera with 
TBS-T for 16- 18 hrs at 4℃. After washing 3 times for 5 min each in TBS-T, the membranes were 
incubated with 1,000-timesdiluted HRP-conjugated rabbit anti-human IgG polyclonal antibody 
(Dako) for 30 min at RT. Finally, signals were developed with Immobilon Western reagent 
(Millipore Corp.). The data were analyzed using DotBlotChipSystem software ver. 4.0 (Dynacom 
Co., Ltd., Chiba, Japan). Normalized signals are presented as the positive intensity minus 
background intensity around the spot. Statistical analysis was performed using the 
Mann-Whitney U-test. The area under the curve (AUC) and best cut-off point were calculated by 
employing receiver operating characteristics (ROC) analysis. 
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3. Results 
3-1. Autoantigens identified by 2DE-IB 
The proteins extracted from LC2/ad-cis cells were separated by 2-DE, transferred onto a PVDF 
membrane, and reacted with pre-treated sera from three patients who were assessed as showing 
PD or PR after platinumbased chemotherapy (Figure 1). Ninety-five and 63 immunoreactive 
spots were detected with pre-treated sera from AC patients who showed PD and PR, respectively. 
In total, 51 proteins including Gal-3 in PD and 12 proteins in PR patients, respectively, were 
identified (Table 2). 
 
3-2. Gal-3 expression in lung cancer cell lines 
To confirm whether Gal-3 was over-expressed in LC2/ad-cis cells compared to that in LC2/ad 
cells, we performed IB and IHC analysis using freshly frozen and formalin-fixed and 
paraffin-embedded LC2/ad cells and LC2/ad-cis cells, respectively (Figure 2). We confirmed that 
the expression of Gal-3 up-regulated in LC/2adcis cells and that positive staining was observed 
in the cytoplasm. 
 
3-3. Extraction of Gal-3 protein using electro-elution method 
We extracted Gal-3 protein from 2DE gels by the electro-elution method. The reactivity of 
extracted Gal-3 protein was confirmed by immunoblot analysis (Figure 3). 
 
3-4. Different reactivity of anti-Gal-3 autoantibody to recombinant or extracted Gal-3 proteins 
Anti-Gal-3 autoantibody in pre-treated sera from lung AC patients did not react with 
recombinant Gal-3 protein, but showed strong reactivity with Gal-3 protein extracted from 
tumor cells (Figure 4). Thus, the serum IgG levels of anti-Gal-3 autoantibody were validated by 
the dot blot analysis with extracted Gal-3 protein from tumor cells. 
 
3-5. Validation of anti-Gal-3 autoantibody 
To confirm its utility as a potential predictive biomarker of the efficacy of platinum-based 
chemotherapy against lung AC, we investigated IgG levels of anti-Gal-3 autoantibody in 
pre-treated sera by dot-blot analysis. The serum IgG levels of anti-Gal-3 autoantibody in PR, PD, 
and SD groups ranged from 190 to 1,070 (median: 550), 650 to 2,300 (median: 1,140), and 310 to 
1,150 (median: 880), respectively. The serum IgG levels of anti-Gal-3 autoantibody were 
significantly higher in the PD group than in PR and SD groups (p=0.0084) (Figure 4 and Figure 
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5 A). An optimal cut-off value of 1,086 was applied based on ROC analysis, and the predictive 
sensitivity and specificity for platinum-based chemotherapy was 67 and 92%, respectively 
(Figure 5 B). The AUC for anti-Gal-3 autoantibody in patients who showed PD compared to SD 
and PR after platinum-based chemotherapy was 0.84. 
 
 
3-6. Gal-3 expression in lung cancer biopsy samples 
To further clarify the relation between Gal-3 expression and the efficacy of platinum-based 
chemotherapy, we compared the stainability and clinical data in 40 pretreated lung biopsy 
samples. We judged the Gal-3 staining as positive when the staining score was 2 or 3 (Figure 6 A), 
while it was negative when the score was 0 or 1 (Figure 6 B). Gal-3 expression was evaluated as 
positive in 10 of 15 (66.7%) PD, 7 of 14 (50.0%) SD, and in 2 of 11 (18.2%) PR patients, 
respectively. The positive rate of Gal-3 was in the order of PD, SD, and PR groups (p=0.0601). 
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4. Discussion 
In the present study, to identify novel biomarkers that can predict the efficacy of 
platinum-based chemotherapy, we performed 2DE-IB to detect autoantigens that are recognized 
by autoantibodies in pre-treated sera from lung AC patients assessed as showing PD or PR often 
platinum-based chemotherapy. Sixty-three autoantigens in total were identified by 2DE-IB. 
We focused on Gal-3 from the identified candidate autoantigens, because it was reported that 
intracellular Gal-3 exhibits activity to suppress drug-induced apoptosis, which was reported to 
be essential for cancer cell survival and tumor progression in various tumor types (Tsuboi et al., 
2007, Park et al., 2008, Saussez et al., 2008, Chiu et al., 2010) and Gal-3 thus has been proposed 
as an antiapoptotic factor in response to chemotherapeutic drugs, and its down-regulation could 
improve the efficacy of anticancer drugs (Fukumori et al., 2006). However, to our knowledge, 
there has been no study on the utility of Gal-3 as an anti-apoptotic factor in lung cancer. They 
also reported that the expression of Gal-3 protein stimulated the phosphorylation of Ser112 of 
Bcl-2- associated death (Bad) protein and down-regulated Bad expression after treatment with 
cisplatin. And, Gal-3 also inhibited mitochondrial depolarization and damage after translocation 
from the nuclei to cytoplasm, resulting in the inhibition of cytochrome c release and caspase-3 
activation (Fukumori et al., 2006). These study suggest that Gal-3 inhibits drug–induced 
apoptosis through the phosphorylation of Bad protein and suppression of the mitochondrial 
apoptosis pathway. 
Cisplatin-induced apoptosis was increased after knocking down the expression of Gal-3, and 
this cytotoxic effect was canceled by roscovitine, an inhibitor of cyclindependent protein kinase 
(Oishi et al., 2007). Wongkham et al. (Wongkham et al., 2009) reported that the cellular levels of 
Gal-3 might contribute to the anti-apoptotic activity and chemoresistance of cholangiocarcinoma 
cells. In the present study, the expression of Gal-3 was up-regulated in cisplatin-resistant 
LC2/ad-cis cells compared with the parental LC2/ad cells, consistent with previous reports 
(Fukumori et al., 2006, Oishi et al., 2007). Although the expression levels of Gal-3 in tumor cells 
have been reported to be correlated with in cisplatin resistance, the association between serum 
IgG levels of anti-Gal-3 autoantibody and cisplatin resistance has not been investigated. 
To confirm the possibility of using anti-Gal-3 autoantibody as a novel predictive marker of the 
efficacy of platinum-based chemotherapy, we measured the serum anti-Gal-3 autoantibody levels 
in patients with diseases assessed as showing PR, SD, or PD following platinumbased treatment 
by dot-blot analysis. We demonstrated that the serum anti-Gal-3 autoantibody levels were 
significantly higher in the PD group than in PR and SD groups (p=0.0084). Furthermore, IHC 
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staining of pretreated lung biopsy samples also showed that the positive rate of Gal-3 was 
highest in the PD group, and was decreased in the order of PD, SD, and PR groups (p=0.052). 
Our results confirmed that the expression of Gal-3 had a role in the anti-apoptotic activity and 
chemoresistance. Taken together, our results suggest the serum anti-Gal-3 autoantibody levels 
might be a useful predictive marker of the efficacy of platinum-based chemotherapy. 
The different reactivity between recombinant and extracted Gal-3 proteins might be caused by 
the presence or absence of post-translational modifications (PTM) (Balan et al., 2010). The 
present data raise the possibility that anti-Gal-3 autoantibody in sera from lung AC patients 
reacts with the modification-received Gal-3 protein, and further studies are necessary to 
investigate this hypothesis. 
In conclusion, we demonstrated that IgG levels of antiGal-3 autoantibody in pre-treated sera 
were significantly higher in patients assessed as showing PD than as PR and SD after 
platinum-based chemotherapy. Our data suggest that the IgG levels of anti-Gal-3 autoantibody 
provide a novel predictive biomarker of the efficacy of platinumbased chemotherapy.
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5. Abstract 
Background: Identification of predictive markers for the efficacy of platinum-based 
chemotherapy is necessary to improve the quality of the life of cancer patients. 
Materials and Methods: We detected proteins recognized by autoantibodies in pretreated sera 
from patients with lung adenocarcinoma (AC) evaluated as showing progressive disease (PD) or 
a partial response (PR) after cisplatin-based chemotherapy by proteomic analysis. Then, the 
levels of the candidate autoantibodies in the pretreated serum were validated by dot-blot 
analysis for 22 AC patients who received platinum-based chemotherapy, and the expression of 
identified proteins was immunohistochemically analyzed in 40 AC biopsy specimens. 
Results: An autoantibody against galectin-3 (Gal-3) was detected in pretreated sera from an AC 
patient with PD. Serum IgG levels of anti-Gal-3 autoantibody were significantly higher in 
patients evaluated with PD than in those with PR and stable disease (SD) (p = 0.0084). 
Furthermore, pretreated biopsy specimens taken from patients evaluated as showing PD 
following platinumbased chemotherapy showed a tendency to have a higher positive rate of 
Gal-3 than those with PR and SD (p = 0.0601). 
Conclusions: These results suggest that serum IgG levels of anti-Gal-3 autoantibody may be 
useful to predict the efficacy of platinum-based chemotherapy for patients with lung AC 
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8．Figure and Table 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Detection of Autoantibodies in Pre-treated Sera from AC Patients who were Treated 
with Platinum-based Chemotherapy by 2DE-IB Analysis. Proteins extracted from LC2/ad-cis 
cells were separated by 2DE. Immunoblot analysis was performed with mixed pre-treated 
sera from AC patients assessed as showing PD (A) or PR (B) as a first-antibody, and the 
reaction was visualized with DAB solution. 
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Figure 2. The Expression of Gal-3 in Cisplatin- Resistant LC2/ad-cis Cells and Sensitive 
LC2/ad Cells. (A) Expression levels of Gal-3 protein were detected by immunoblot analysis. 
Beta-actin was used as an internal control. (B) Expression levels of Gal-3 were normalized by 
expression levels of beta-actin and presented as Relative Light Units (RLU). Cytoplasmic 
staining of Gal-3 in LC2/ad cells (C) and LC2/ad-cis cells (D). 
 -18- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.  Gal-3 protein extracted from 2DE gels was confirmed by immunoblotting with 
anti-Gal-3 antibody. 
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Figure 4.  The reactivity of anti-Gal-3 autoantibody to recombinant or extracted Gal-3 
proteins by dot-blot analysis.  Extracted proteins using the electro-elution method or 
recombinant Gal-3 proteins were spotted onto PVDF membranes.  The membranes were 
reacted with pretreated sera from AC patients showing PR or PD.  For Gal-3 protein 
extracted from 2-DE gels, strong or weak signals of anti-Gal-3 autoantibody were detected in 
two each of AC patients diagnosed as showing PD or PR, respectively.  However, no clear 
signals were detected with recombinant Gal-3 protein. 
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Figure 5. Anti-Gal-3 Autoantibody Levels in Pre- Treated Sera from Lung Cancer Patients by 
Dot-blot Analysis. (A) The median Gal-3 autoantibody level in pre-treated sera from patients 
assessed as showing PR and SD or PD was 873 or 1,140. Anti-Gal-3 autoantibody levels were 
significantly higher in PD patients than PR and SD patients (p < 0.0084). (B) Receiver 
operating characteristic curve (ROC) analysis of serum anti-Gal-3 autoantibody levels as a 
predictive marker of the efficacy of platinum-based chemotherapy against lung 
adenocarcinoma. The corresponding area under the curve was 0.84 for anti-Gal-3 
autoantibody. With 92% specificity, the sensitivity of anti-Gal-3 autoantibody for patients 
assessed as showing PD was 67%, at a cut-off value corresponding to 1,086. 
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Figure 6. Expression of Gal-3 in lung cancer biopsy samples. (A) The section from patients 
who assessed as showing progressive disease (PD) following platinum-based chemotherapy 
was evaluated as Gal-3-positive. (B) The section from patients who assessed as showing 
partial response (PR) to platinum-based chemotherapy was evaluated as Gal-3-negative. 
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Table 1.  Combinations of platinum-based chemotherapy in patients in this study 
Regimen n 
Response 
PR SD PD 
CDDP + GEM 7 2 3 2 
CDDP+DOC 1 1 0 0 
CBDCA+GEM 3 0 0 3 
CBDCA+DOC 2 0 1 1 
CBDCA+PTX 9 4 2 3 
CDDP, cisplatin; CBDCA, Carboplatin; GEM, gemcitabine; DOC, docetaxel; PTX, paclitaxel 
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